



Lucie Heinzerling

Contact

Lucie Heinzerling

Units

Dermatologie | Venerologie | Allergologie

Publications (36)

Heinzerling L, Pichler W, Anliker M. Acute generalized exanthematous pustulosis induced by methylphenidate: a new adverse effect. *Arch Dermatol* 2011; 147:872-3.

Heinzerling L, Anliker M, Müller J, Schlaepi M, von Moos R. Sarcoidosis induced by interferon-? in melanoma patients: incidence, clinical manifestations, and management strategies. *J Immunother* 2010; 33:834-9.

Schlaepi M, Anliker M, Heinzerling L, von Moos R. Malignes Melanom - Inzidenz, Früherkennung und therapeutische Optionen. *Facharzt* 2010; 2:4-7.

Bousquet P, Gramicci C, Papadopoulos N, Haahtela T, Kowalski M, Magyar P, Muraközi G, Orosz M, Röhneit C, Stingl G, Todo-Bom A, von Mutius E, Wiesner A, Wöhrl S, Bousquet J, Giavi S, Fokkens W, Burbach G, Heinzerling L, Edenthaler G, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet-Rouanet L, Demoly P, Bresciani M, Bruno A, Gjomarkaj M, Canonica G, Darsow U, Durham S, Zuberbier T. GA2LEN skin test study III: minimum battery of test inhalant allergens needed in epidemiological studies in patients. *Allergy* 2009; 64:1656-62.

Burbach G, Gjomarkaj M, Gramicci C, Haahtela T, Kowalski M, Magyar P, Muraközi G, Orosz M, Papadopoulos N, Röhneit C, Stingl G, Todo-Bom A, von Mutius E, Wiesner A, Wöhrl S, Giavi S, Fokkens W, Heinzerling L, Edenthaler G, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet J, Bousquet-Rouanet L, Bousquet P, Bresciani M, Bruno A, Canonica G, Darsow U, Demoly P, Durham S, Zuberbier T. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. *Allergy* 2009; 64:1507-15.

Heinzerling L, Gjomarkaj M, Gramicci C, Haahtela T, Kowalski M, Magyar P, Muraközi G, Orosz M, Papadopoulos N, Röhneit C, Stingl G, Todo-Bom A, von Mutius E, Wiesner A, Wöhrl S, Giavi S, Fokkens W, Durham S, Burbach G, Edenthaler G, Bachert C, Bindslev-Jensen C, Bonini S, Bousquet J, Bousquet-Rouanet L, Bousquet P, Bresciani M, Bruno A, Burney P, Canonica G, Darsow U, Demoly P, Zuberbier T. GA(2)LEN skin test study I: GA(2)LEN harmonization of skin prick testing: novel sensitization patterns for inhalant allergens in Europe. *Allergy* 2009; 64:1498-506.

Burbach G, Heinzerling L, Röhneit C, Bergmann K, Behrendt H, Zuberbier T, GA(2)LEN study. Ragweed sensitization in Europe - GA(2)LEN study suggests increasing prevalence. *Allergy* 2009; 64:664-5.

Shaheen S, Bruno A, Pace E, Bonini S, Fokkens W, Weersink E, Loureiro C, Todo-Bom A, Villanueva C, Sanjuas C, Zock J, Janson C, Burney P, Selenium and Asthma Research Integration project, Gjomarkaj M, Heinzerling L, Bergmann K, Potts J, Gnatiuc L, Makowska J, Kowalski M, Joos G, van Zele T, van Durme Y, De Ruddere I, Wöhrl S, Godnic-Cvar J, Skadhauge L, Thomsen G, Zuberbier T, GA2LEN. The relation between paracetamol use and asthma: a GA2LEN European case-control study. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2008; 32:1231-6.

Janson C, Bonini S, Pace E, Bruno A, Gjomarkaj M, Zannikos K, Xepapadaki P, Papadopoulos N, Hildenberg A, Kosche B, Bresciani M, Gramicci C, Lundback B, Zock J, Sanjuas C, Villanueva C, Loureiro C, Bakkeheim E, Carlsen K, Weersink E, Fokkens W, Al-Fakhri N, Renz H, van Zele T, Van Cauwenberge P, Joos G, Shaheen S, Gnatiuc L, Phillips J, Kowalski M, Makowska J, Potts J, Verbruggen K, van Durme Y, Heinzerling L, Bergmann K, Zuberbier T, Thomsen G, Skadhauge L, Salameh B, Godnic-Cvar J, Wöhrl S, Derudder I, Burney P. A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project. *Allergy* 2008; 63:865-71.

Sterry W, Heinzerling L. Clinical research in cutaneous T-cell lymphoma moving forward. *Archives of dermatology* 2008; 144:786-7.

Heinzerling L, Raile K, Rochlitz H, Zuberbier T, Worm M. Insulin allergy: clinical manifestations and management strategies. *Allergy* 2008; 63:148-55.

Zuberbier T, Heinzerling L, Bieber T, Schauer U, Klebs S, Bräutigam M. Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis. *Dermatology (Basel, Switzerland)* 2007; 215:325-30.

Rotty J, Heinzerling L, Schurmann D, Suttorp N. Interleukin-2: a potential treatment option for postherpetic neuralgia?. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America* 2006; 43:e109-10.

Künzi V, Oberholzer P, Heinzerling L, Dummer R, Naim H. Recombinant measles virus induces cytolysis of cutaneous T-cell lymphoma in vitro and in vivo. *The Journal of investigative dermatology* 2006; 126:2525-32.

Heinzerling L, von Baehr V, Liebenthal C, von Baehr R, Volk H. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. *Journal of clinical immunology* 2006; 26:347-59.

Heinzerling L, Worm M, Bergmann K, Zuberbier T. Sublingual immunotherapy. *Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG* 2006; 4:428-33; quiz 434-5.

Heinzerling L, Basch V, Maloy K, Johansen P, Senti G, Wüthrich B, Storni T, Kündig T. Critical role for DNA vaccination frequency in induction of antigen-specific cytotoxic responses. *Vaccine* 2006; 24:1389-94.

Heinzerling L, Kowalski M, Kopp T, Lahoz C, Lodrup Carlsen K, Papadopoulos N, Ring J, Schmid-Grendelmeier P, Vignola A, Wöhrl S, Jessberger B, van Hoecke H, Haahtela T, Frew A, Bindslev-Jensen C, Bonini S, Bousquet J, Bresciani M, Carlsen K, Van Cauwenberge P, Darsow U, Fokkens W, Zuberbier T. Standard skin prick testing and sensitization to inhalant allergens across Europe--a survey from the GALEN network. *Allergy* 2005; 60:1287-300.

Heinzerling L, Künzi V, Oberholzer P, Kündig T, Naim H, Dummer R. Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. *Blood* 2005; 106:2287-94.

Heinzerling L. Attitudes of traditional healers towards Western medicine in rural Cameroon. *Tropical doctor* 2005; 35:161-4.

Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer P, Schultz J, Elzaouk L, Pavlovic J, Moelling K. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. *Human gene therapy* 2005; 16:35-48.

Keyser J, Schultz J, Ladell K, Elzaouk L, Heinzerling L, Pavlovic J, Moelling K. IP-10-encoding plasmid DNA therapy exhibits anti-tumor and anti-metastatic efficiency. *Experimental dermatology* 2004; 13:380-90.

Heinzerling L, Kempf W, Kamarashev J, Hafner J, Nestle F. Treatment of verrucous carcinoma with imiquimod and CO₂ laser ablation. *Dermatology (Basel, Switzerland)* 2003; 207:119-22.

Heinzerling L, Dummer R, Pavlovic J, Schultz J, Burg G, Moelling K. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice. *Experimental dermatology* 2002; 11:232-40.

Rochlitz C, Dietrich P, Herrmann R, Morant R, Heinzerling L, Escudier B, Baudin M, Acres B, Squiban P, Cavalli F, Jantschkeff P, Dreno B, Dummer R. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. *Cancer gene therapy* 2002; 9:289-95.

Heinzerling L, Dummer R, Burg G, Schmid-Grendelmeier P. Panniculitis after subcutaneous injection of interferon beta in a multiple sclerosis patient. *European journal of dermatology : EJD* 2002; 12:194-7.

Erdmann I, Scheidegger E, Koch F, Heinzerling L, Odermatt B, Burg G, Lowe J, Kündig T. Fucosyltransferase VII-deficient mice with defective E-, P-, and L-selectin ligands show impaired CD4+ and CD8+ T cell migration into the skin, but normal extravasation into visceral organs. *Journal of immunology (Baltimore, Md. : 1950)* 2002; 168:2139-46.

Heinzerling L, Dummer R, Panizzon R, Bloch P, Barbezat R, Burg G, Task force 'swiss cancer' of the swiss cancer league. Prevention campaign against skin cancer. *Dermatology (Basel, Switzerland)* 2002; 205:229-33.

Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle F. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. *Dermatology (Basel, Switzerland)* 2002; 205:213-6.

Heinzerling L, Feige K, Rieder S, Akens M, Dummer R, Stranzinger G, Moelling K. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. *Journal of molecular medicine (Berlin, Germany)* 2001; 78:692-702.

Schultz J, Heinzerling L, Pavlovic J, Moelling K. Induction of long-lasting cytokine effect by injection of IL-12 encoding plasmid DNA. *Cancer gene therapy* 2000; 7:1557-65.

Heinzerling L, Urbanek M, Funk J, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. *Cancer* 2000; 89:1835-44.

Dummer R, Heinzerling L, Schmid M, Burg G. [Immuno-intervention in cutaneous lymphomas]. *Praxis* 2000; 89:1471-6.

Heinzerling L, Dummer R, Kempf W, Schmid M, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. *Archives of dermatology* 2000; 136:374-8.

Heinzerling L, Dummer R, Wildberger H, Burg G. Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient. *Dermatology (Basel, Switzerland)* 2000; 201:154-7.

operschall E, Schuh T, Heinzerling L, Pavlovic J, Moelling K. Enhanced protection against viral infection by co-administration of plasmid DNA coding for viral antigen and cytokines in mice. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 1999; 13:17-27.

Projects (5)

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma; Short Title: GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma

Fundamental Research - Dec 22, 2010 - Dec 31, 2015

Automatically Closed

clinical study; The tolerance of acid textiles (pH 5.5–6.5) in patients with atopic and/or dry skin – a randomized, double blind, placebo-controlled study conducted by Kantonsspital St. Gallen

Clinical Studies - Dec 22, 2010 - Dec 22, 2010

Completed

Assessment of a novel lyophilizable virosome formulation as an adjuvant to the induction of effector cells specific for Melan-A/MART-1 melanoma associated antigen

Fundamental Research - Feb 1, 2010 - Jan 31, 2011

Completed

A Phase II, randomized, double-blind, placebo

Clinical Studies - Dec 7, 2009 - Oct 30, 2010

Completed

A randomized, double-blind, placebo controlled Phase

Clinical Studies - Dec 7, 2009 - Nov 25, 2010

Completed